Insights into New-onset Arthritis in Patients with Hidradenitis Suppurativa

Patricia Garbayo-Salmons,Mireia Moreno Martínez-Losa,Vicente Exposito-Serrano,Miquel Ribera,Joan Calvet

DOI: https://doi.org/10.2340/actadv.v104.40145

2024-06-25

Abstract:Abstract is missing (Short communication)

dermatology

What problem does this paper attempt to address?

An Update on Hidradenitis Suppurativa (Part I): Epidemiology, Clinical Aspects, and Definition of Disease Severity

A Martorell,F J García-Martínez,D Jiménez-Gallo,J C Pascual,J Pereyra-Rodriguez,L Salgado,E Vilarrasa

DOI: https://doi.org/10.1016/j.ad.2015.06.004

Abstract:Hidradenitis suppurativa is a chronic inflammatory disorder that has attracted increasing attention in recent years due to underestimations of prevalence and the considerable impact of the condition on interpersonal relationships, physical appearance, self-esteem, and body image. Although hidradenitis suppurative has a significant psychological impact on patients and can even cause physical limitations when thick scarring results in limb mobility limitation, until very recently little evidence was available relating to its epidemiology, etiology, or pathogenesis. In this review, we highlight the latest advances in our understanding of the epidemiological and clinical aspects of hidradenitis suppurativa. We will also look at the different classification systems for hidradenitis suppurativa and discuss the emergence of skin ultrasound as a promising technique for monitoring the course of this chronic inflammatory disease.
Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study

Sofía Haselgruber,Pablo Fernández-Crehuet-Serrano,María Dolores Fernández-Ballesteros,Alicia Padial-Gómez,Juan Carlos Hernández-Rodríguez,Juan Ortiz-Álvarez,Pedro Navarro-Guillamón,Cristina Membrive-Jiménez,Carlos Cuenca-Barrales,Alejandro Molina-Leyva

DOI: https://doi.org/10.1007/s13555-024-01209-w

2024-06-20

Dermatology and Therapy

Abstract:The concept of a window of opportunity in hidradenitis suppurativa (HS) management suggests that early initiation of biological therapy leads to better outcomes, though its timing remains uncertain.

dermatology
Hidradenitis Suppurativa from a Multi-Omic Scope

Patricia Garbayo-Salmons,Ester Saus,Vicente Exposito-Serrano,Mireia Moreno,Mireia Sàbat,Joan Calvet

DOI: https://doi.org/10.1177/12034754241293138

2024-11-04

Journal of Cutaneous Medicine and Surgery

Abstract:Journal of Cutaneous Medicine and Surgery, Ahead of Print. Hidradenitis suppurativa (HS) is recognized as a systemic immune-mediated disease (IMID), sharing genetic and environmental risk factors with other IMIDs such as inflammatory bowel disease and psoriasis. Over time, correlating clinical findings with genetic, proteomic, and metabolomic results has been challenging due to diverse sampling methods, analysis techniques, and the use of variable clinical phenotype descriptions across studies. This review aims to summarize the results from various omics fields to explore the etiopathology of HS. Genetic studies highlight defects in Notch and γ-secretase signaling and inflammasome function. Syndromic HS involves specific mutations in autoinflammatory syndromes such as pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) and pyoderma gangrenosum, acne, and HS (PASH). Proteomic analyses reveal key inflammatory pathways indicating activation of both innate and adaptive immunity. Additionally, microbiome studies show an increased presence of anaerobes like Prevotella in HS lesions and a decreased presence of commensals such as Staphylococcus epidermidis. Gut microbiota dysbiosis, particularly involving Ruminococcus gnavus and Clostridium ramosum, is associated with HS. Moreover, metabolomic profiling indicates dysregulated tryptophan catabolism and lipid metabolism, with increased 5-lipoxygenase-derived metabolites and odd-chain fatty acids suggesting bacterial involvement. In summary, despite advances, robust associations between genetics, proteomics, microbiome, and metabolomics in HS are still lacking. Integrating these datasets could identify new clinical phenotypes, genetic predispositions, microbial signatures, and therapeutic targets, enhancing personalized treatment strategies and biomarker discovery for HS classification, prognosis, and treatment response.

dermatology
The Nationwide Epidemiology of Patients Treated for Hidradenitis Suppurativa by a Dermatologist in the Faroe Islands

Amanda T. Brosbøl,Dorra Bouazzi,Gregor B.E. Jemec,Ditte M.L. Saunte

DOI: https://doi.org/10.2340/actadv.v104.41138

2024-08-28

Abstract:Abstract is missing (Short communication)

dermatology
Prevalence and Predictors of Inflammatory Arthritis in Hidradenitis Suppurativa

Sheena Maureen T. Sy,Lihi Eder,Dana Jerome,Chikaodili Obetta,Hayley McKee,Reza Mirza,Elisabeth Pek,Vincent Piguet,Raed Alhusayen

DOI: https://doi.org/10.1111/exd.15194

2024-10-14

Experimental Dermatology

Abstract:Hidradenitis Suppurativa (HS) is a chronic, debilitating, auto‐inflammatory condition often associated with inflammatory arthritis, significantly impacting patients' quality of life. Early diagnosis of both conditions is crucial for optimal management. The objective of this study was to determine the prevalence and factors associated with the development of inflammatory arthritis among HS patients. A cross‐sectional study was conducted between November 2021 and February 2023 at an academic dermatology centre in Canada. Adult patients with HS were consecutively sampled, and 52 patients consented to participate and completed assessments. Variables examined included age, sex, HS severity, treatment, ethnicity, family history, lifestyle factors and comorbidities. The main outcomes were rheumatologist‐confirmed inflammatory arthritis diagnosis and associated risk factors. Among 52 patients (24 males, 28 females; mean age: 37.4 years), 12 had inflammatory arthritis. Multivariate analysis revealed that Blacks (OR = 0.10, p

dermatology
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

James G Krueger,John Frew,Gregor B E Jemec,Alexa B Kimball,Brian Kirby,Falk G Bechara,Kristina Navrazhina,Errol Prens,Kristian Reich,Eva Cullen,Kerstin Wolk

DOI: https://doi.org/10.1093/bjd/ljad345

2024-01-23

Abstract:Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with a high unmet medical need. The prevalence of HS reported in most studies is 1-2%, although it is likely to be under-reported and estimates vary globally owing to variance in data collection methods, ethnicity, geographical location and under-diagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses and draining tunnels commonly affecting the axillary, anogenital, inguinal and perianal/gluteal areas. Over time, chronic uncontrolled inflammation results in irreversible tissue destruction and scarring. Although the pathophysiology of HS has not been fully elucidated, the tumour necrosis factor (TNF)-α and interleukin (IL)-17 pathways have an important role, involving multiple cytokines. Currently, treatment options include topical medications; systemic therapies, including repeated and/or rotational courses of systemic antibiotics, retinoids and hormonal therapies; and various surgical procedures. The anti-TNF-α antibody adalimumab is currently the only biologic approved by both the US Food and Drug Administration and the European Medicines Agency for HS; however, its efficacy varies, with a clinical response reported in approximately 50% of patients in phase III trials. HS is a rapidly evolving field of discovery, with a diverse range of agents with distinct mechanisms of action currently being explored in clinical trials. Several other promising therapeutic targets have recently emerged, and agents targeting the IL-17 and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways are the most advanced in ongoing or completed phase III clinical trials. Alongside limited therapeutic options, significant challenges remain in terms of diagnosis and disease management, with a need for better treatment outcomes. Other unmet needs include significant diagnostic delays, thus missing the therapeutic 'window of opportunity'; the lack of standardized outcome measures in clinical trials; and the lack of established, well-defined disease phenotypes and biomarkers.
Profound Sexual Dysfunction Among Patients with Hidradenitis Suppurativa: A Cross-sectional Study

Piotr K. Krajewski,Alexandra Strobel,Michael Schultheis,Petra Staubach,Stephan Grabbe,Katharina Hennig,Lukasz Matusiak,Esther von Stebut,Simone Garcovich,Hans Bayer,Marcus Heise,Uwe Kirschner,Georgios Nikolakis,Jacek C. Szepietowski

DOI: https://doi.org/10.1007/s13555-024-01196-y

2024-06-14

Dermatology and Therapy

Abstract:Sexual health, a critical aspect of overall well-being, is often compromised in individuals with chronic disorders. Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that mainly affects intertriginous areas, potentially impacting sexual health as a result of its specific symptoms and psychosocial burden.

dermatology
The most recent advances in understanding and managing hidradenitis suppurativa

Shanthi Narla,Alexis B Lyons,Iltefat H Hamzavi

DOI: https://doi.org/10.12688/f1000research.26083.1

Abstract:Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients' growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.
Prevalence of Musculoskeletal Symptoms in Patients With Hidradenitis Suppurativa and Associated Factors: Cross-Sectional Study

Hayley McKee,Lihi Eder,Dana Jerome,Reza D Mirza,Chikaodili Obetta,Elisabeth Pek,Vincent Piguet,Raed Alhusayen

DOI: https://doi.org/10.2196/58989

2024-08-22

Abstract:The prevalence of and factors associated with musculoskeletal (MSK) symptoms in patients with hidradenitis suppurativa (HS) have yet to be elucidated. Given the association between HS and inflammatory comorbidities, understanding the burden of MSK symptoms in patients with HS is crucial for patient-centered care. Our objective was to describe the prevalence of and factors associated with MSK symptoms in patients with HS. A cross-sectional study of 78 consecutive patients recruited between November 2021 and February 2023 with a dermatology-confirmed diagnosis of HS, irrespective of MSK symptoms, was performed. The average age of participants (n=78) was 37 (SD 12.2) years, and the average age at symptom onset was 23 (SD 12.1) years; 54% (n=42) of participants identified as women, and 46% (n=36) as men. The most common comorbidities included depression (n=17, 22%) and preexisting arthritis (n=12, 16%). Approximately 24% (n=18) of participants reported prolonged morning stiffness. In a multivariate regression, depression was significantly associated with morning stiffness (odds ratio [OR] 6.1, 95% CI 1.4-26.1; P=.02), while female sex was significantly associated with arthralgia (OR 19.1, 95% CI 1.6-235.2; P=.02). Every patient with depression reported arthralgia. We highlight the high prevalence of MSK symptoms among patients with HS and note the interplay between depression and MSK symptoms, with each one potentially contributing to the other.
Real‐world adalimumab survival and discontinuation factors in hidradenitis suppurativa

Patricia Garbayo‐Salmons,Eva Vilarrasa,Julio Bassas‐Vila,Veronica Mora‐Fernández,Irene Fuertes,Mar Luque‐Luna,Rosa Fornons‐Servent,Gemma Martin‐Ezquerra,Rafael Sergio Aguayo‐Ortiz,Joan Ceravalls,Jordi Mollet,Álvaro Gómez Tomás,Emili Masferrer,Oriol Corral‐Magaña,Clara Matas‐Nadal,Jorge del Estal,Diana Fuertes Bailón,Joan Calvet,Jorge Romaní

DOI: https://doi.org/10.1111/jdv.20044

2024-05-02

Journal of the European Academy of Dermatology and Venereology

Abstract:Background and Objectives Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID‐19 pandemic. Methods We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan–Meier survival curves and compared between the subgroups via stratified log‐rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression. Results Overall, 50.1% were females with a mean age of 43.5 ± 1 years and a mean BMI of 29.5 ± 6.7. At the start of ADA, 95.29% were biologic‐naïve and 24.63% had undergone surgical treatment. During follow‐up, 9.46% of patients required dose escalation, while 39.92% interrupted ADA. Concomitant therapy was used in 64.89% of cases. A subanalyses comparing pre‐ and post‐pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID‐19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56.2 months (95% CI 51.2 to 80.3). The primary causes for discontinuation were inefficacy (51.69%), followed by adverse effects (21.35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation. Conclusions ADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival.

dermatology
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study

Hilliard T. Brydges,Ogechukwu C. Onuh,Rebecca Friedman,Joy Barrett,Rebecca A. Betensky,Catherine P. Lu,Avrom S. Caplan,Afsaneh Alavi,Ernest S. Chiu

DOI: https://doi.org/10.1007/s40257-024-00844-5

2024-02-11

American Journal of Clinical Dermatology

Abstract:Hidradenitis suppurativa (HS) is a debilitating cutaneous disease characterized by severe painful inflammatory nodules/abscesses. At present, data regarding the epidemiology and pathophysiology of this disease are limited.

dermatology
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study

Fernandez-Crehuet, Pablo

DOI: https://doi.org/10.1007/s13555-023-00906-2

2023-03-10

Dermatology and Therapy

Abstract:Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties. The aim of this study is to evaluate the effectiveness and safety of secukinumab in patients with moderate to severe HS after 16 weeks of treatment, and to explore potential predictors of clinical response to the drug.

dermatology
Epidemiology of Hidradenitis Suppurativa: Current Status

Diana Díaz,Alejandra Rivera,Valentina Otero,Lili Rueda

DOI: https://doi.org/10.1007/s13671-022-00372-7

2022-10-11

Current Dermatology Reports

Abstract:Abstract Purpose of Review This review aimed to provide a comprehensive and current state of art about epidemiology and clinical aspects of the HS. Recent Findings Our search yielded 17 articles that included studies that showed a prevalence range from 0.00033 to 1.4%. Incidence data is limited. HS is more prevalent in women than in men. The highest prevalence is found in the third and fourth decade of life. The most frequent localizations are the inguinal, axillary, and perianal regions. There are associations between HS and obesity (OR 2.09), hypertension (OR 1.84), and dyslipidemia (OR 4.06), among others. Summary Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by occlusion of hair follicles as a primary pathogenic factor. It affects areas of the body with apocrine glands, predominantly in the axillary, inguinal, intermammary, and anogenital regions. Clinically, its manifestations vary from inflammatory nodules and abscesses to the formation of sinus tracts and scarring. HS used to be considered a disorder of apocrine glands; today, it is considered a disease of the pilosebaceous unit associated with an immune imbalance in a genetically predisposed individual, thus linked to other autoimmune diseases.
Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution

Faith D. Huynh,Giovanni Damiani,Christopher G. Bunick

DOI: https://doi.org/10.3390/antibiotics13030268

2024-03-18

Antibiotics

Abstract:Hidradenitis suppurativa (HS), or acne inversa, is a chronic inflammatory dermatological condition characterized by painful and recurrent nodules and purulent abscesses. HS can have a devastating impact on the quality of life of patients. This condition is commonly localized to the axilla, groin, perineal, and inframammary regions, and can develop fistulas and sinus tracts over time. Its pathogenesis remains elusive and is best characterized at the moment as multi-factorial. Additionally, questions remain about the role of cutaneous dysbiosis as a primary HS trigger or as a secondary perturbation due to HS inflammation. This article features works in relation to HS and its interplay with bacterial microflora. We address current treatment approaches and their impact on HS-related bacteria, as well as areas of therapeutic innovation. In the future, disease-modifying or remittive therapy will likely combine an advanced/targeted anti-inflammatory approach with one that effectively modulates cutaneous and deep tissue dysbiosis.

pharmacology & pharmacy,infectious diseases
P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

L Madero Velázquez,R De Francisco,B Herreros,C Yagüe,L Bujanda,X Calvet,A Ponferrada,M Aguas,F Rodríguez-Moranta,I Marin- Jiménez,L Catala,F Gomollon,J Huguet,F Mesonero,D Monfort,M Sierra,L Igualada,E Ricart,M González-Vivó,M J García,A Hernandez- Camba,A Elorza,L Zabalza- San Martín,L Ramos,M D Martín Arranz,I Ruiz-Nuñez,P Martinez-Montiel,P Soto,C Roig,M L Molina,M Mañona,C Taxonera,M Barreiro- de Acosta,J P Gisbert,P Ramírez,R Lorente,Y Zabana,B Botella,E Domènech,A Gutierrez-Casbas

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0360

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Hidradenitis suppurativa (HS) is a relapsing skin disease. Evidence supports an association between HS and inflammatory bowel disease(IBD). Aim, to explore the characteristics of patients with IBD and HS(IBD-HS) and to compare with IBD patients without HS(controls). Methods Retrospective, observational, multi-centre, case-control study of the Spanish nationwide ENEIDA registry. We selected all IBD patients with HS confirmed by a dermatologist. Patients were matched 2:1 by hospital and year of diagnosis with controls. A form regarding HS was completed by researchers. Efficacy of HS therapy was defined as≥50% reduction in the number of inflammatory skin lesions. Results A total of 273 patients(mean age 43±12 years) with IBD-HS and 546 matched controls(mean age 53±15) were included. Diagnosis of IBD preceded HS diagnosis in 208 IBD-HS patients(77%). Female sex(62 vs 44%, p=0.0001), smoking habit(45 vs 15%, p=0.0001), Crohn disease(CD) (82 vs 54%, p=0.0001), ileocolonic CD location(46 vs 36%, p=0.0001), perianal disease(55 vs 20%, p=0.0001), extensive ulcerative colitis (59 vs 45% p < 0.05) and extraintestinal manifestations(EIM)(joint and cutaneous)(38 vs 17, p=0.0001) were more frequent in IBD-HS than among controls. Body mass index(BMI) was higher in IBD-HS vs controls(28 ±7 vs 26±4, p=0.05). Hypotiroidism (4,4 vs 1,1%, p < 0.05) and psychiatric disorders(18% vs 2%, p< 0.05) were more prevalent in IBD-HS cohort. More IBD-HS patients underwent abdominal(29 vs 23, p=0,04) and perianal (35 vs 8%, p=0.000) IBD-related surgeries. The use of biologics was more frequent in IBD-HS patients(73 vs 54%, p=0.0001). HS characteristics are shown in Table 1. HS affected mainly axillary(57%) and inguinal regions (57%) followed by genital(42%), perianal(31%), buttocks(27%) and breast(17%). Paradoxical HS was observed in 19(7%) IBD-HS patients, associated to infliximab(IFX)(4, 21%), adalimumab(ADA)(11, 58%) and ustekinumab (UST)(3,16%), leading to stop them in 7(41%) patients. Regarding HS therapy, the efficacy to treatments was: IFX(30/49, 59%), ADA(49/86, 57%), UST(31/49, 69%), and other biologic(5/14, 36%). Conclusion In the largest cohort of IBD-HS patients ever reported, female sex, BMI, CD, smoking, and perianal disease are risk factors for HS among IBD patients. Skin and joint EMI, abdominal and perianal IBD surgeries and need of biologic therapy are more frequent among IBD-HS patients than in controls. Notably, more than half of these patients responded to anti-TNF while 2 thirds of those treated with UST exhibited a favorable response regarding HS lesions.

gastroenterology & hepatology
Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management—A Systematic Review

Michael Joseph Diaz,Shaliz Aflatooni,Parsa Abdi,Rina Li,Michelle Robert Anthony,Sphurti Neelam,Chris Farkouh,Jasmine Thuy Tran,Steven Svoboda,Mahtab Forouzandeh,Rodrigo H. Valdes Rodriguez

DOI: https://doi.org/10.3390/cimb45050280

2023-05-17

Current Issues in Molecular Biology

Abstract:Hidradenitis suppurativa is a chronic inflammatory skin condition that affects the hair follicles in areas of the body with apocrine glands. The condition is characterized by recurrent, painful nodules, abscesses, and draining sinuses that can lead to scarring and disfigurement. In this present study, we provide a focused evaluation of recent developments in hidradenitis suppurativa research, including novel therapeutics and promising biomarkers that may facilitate clinical diagnosis and treatment. We conducted a systematic review of controlled trials, randomized controlled trials, meta-analyses, case reports, and Cochrane Review articles in accordance with the PRISMA guidelines. The Cochrane Library, PubMed, EMBASE, and Epistemonikos databases were queried via Title/Abstract screen. Eligibility criteria included the following: (1) has a primary focus on hidradenitis suppurativa, (2) includes measurable outcomes data with robust comparators, (3) details the sample population, (4) English language, and (5) archived as full-text journal articles. A total of 42 eligible articles were selected for review. Qualitative evaluation identified numerous developments in our understanding of the disease’s multiple potential etiologies, pathophysiology, and treatment options. It is important for individuals with hidradenitis suppurativa to work closely with a healthcare provider to develop a comprehensive treatment plan that addresses their individual needs and goals. To meet this objective, providers must keep current with developments in the genetic, immunological, microbiological, and environmental factors contributing to the disease’s development and progression.

biochemistry & molecular biology
Insights into Gut Microbiome Composition in Hidradenitis Suppurativa: A Comprehensive Examination of Dietary Habits and Environmental Influences

Edyta Lelonek,Jacek C. Szepietowski

DOI: https://doi.org/10.3390/nu16111776

IF: 5.9

2024-06-05

Nutrients

Abstract:This study explores the relationship between dietary habits, environmental influences, and gut microbiome composition in individuals with hidradenitis suppurativa (HS), a chronic inflammatory skin condition. A cohort of 80 participants, equally divided into HS patients and healthy controls, was assessed through comprehensive questionnaires capturing demographics, dietary habits, and other health-related information. Fecal samples were collected and analyzed using next-generation sequencing to examine microbiome composition. Despite previous studies suggesting gut dysbiosis in HS, this research found no significant differences in alpha-diversity and Shannon diversity index between the groups. However, significant disparities in dietary habits were observed, with HS patients showing higher sugar and milk consumption. The study also identified a significant correlation between coffee consumption and the presence of certain bacterial genera. While the study did not reveal major differences in microbiome diversity, the findings on dietary habits and specific microbiome components suggest potential targets for therapeutic intervention. These results underscore the importance of further research into the gut–skin axis and its role in HS, aiming to enhance management strategies through dietary modifications and lifestyle interventions.

nutrition & dietetics
S1131 Disease Outcomes in Patients With Inflammatory Bowel Disease and Concurrent Hidradenitis Suppurativa: A Nationwide Cohort Study

Katherine Shepherd,Ethan M. Cohen,Joshua Kirkpatrick,Alyssa Lorenze,Zach Kovach,Jennifer Hadam-Veverka

DOI: https://doi.org/10.14309/01.ajg.0001033892.17471.d6

2024-10-26

The American Journal of Gastroenterology

Abstract:Hidradenitis suppurativa (HS) is an inflammatory skin condition defined by debilitating skin lesions that form in areas with high volumes of apocrine glands, with the most common areas being the axillary, inguinal, and anogenital regions. Inflammatory bowel disease (IBD), consisting of Ulcerative colitis (UC) and Crohn's disease (CD), is a well-known inflammatory disorder of the bowel with well-documented extraintestinal manifestations. Studies have proposed a link between HS and IBD due to the inflammatory nature of both conditions, and while TNF-alpha inhibitors are an effective treatment of both diseases, data on the outcomes of IBD in this population is limited. We aim to perform the largest retrospective cohort study to date in this population, looking at the IBD outcomes of concurrent HS and IBD.

gastroenterology & hepatology
Clinical Epidemiology and Management of Hidradenitis Suppurativa

Christopher J Sayed,Jennifer L Hsiao,Martin M Okun,Hidradenitis Suppurativa Foundation Women's Health Subcommittee

DOI: https://doi.org/10.1097/AOG.0000000000004321

2021-04-01

Abstract:Hidradenitis suppurativa is a chronic immune-mediated inflammatory skin disease with a prevalence of 0.1-1%, characterized by nodules and abscesses in the axillae, groin, and inframammary areas, sometimes developing into tunnels (or fistulas) and scars. Because hidradenitis suppurativa is more common in women and in those aged 18-40 years, obstetrician-gynecologists (ob-gyns) have the opportunity to diagnose, educate, initiate treatment, and coordinate care with ancillary health care professionals. The recently published North American treatment guidelines, along with management information for patients with hidradenitis suppurativa who are pregnant or breastfeeding, are summarized. By diagnosing and optimizing hidradenitis suppurativa treatment early in the disease course, ob-gyns can reduce morbidity, with the potential to favorably alter disease trajectory.
Hidradenitis Suppurativa: A Literature Review Comparing Current Therapeutic Modalities

Urvashi Rathod,Pooja N Prasad,Bhaumikkumar Mukeshbhai Patel,Brinda Patel,Chintankumar Patel,Siddharth Kamal Gandhi,Priyansh Patel

DOI: https://doi.org/10.7759/cureus.43695

2023-08-18

Cureus

Abstract:Hidradenitis suppurativa (HS) is a disease with a poor prognosis, often misinterpreted as an infection, with the highest impact on the patient's quality of life among all the assessed dermatological diseases. The main aim of this study was to compare various therapeutic interventions that are currently available for the treatment of HS. The pathogenesis of HS is not well understood, but it is mostly multifactorial involving a number of factors like genetic factors, androgens, local immunity, microflora, smoking, and obesity. Despite limited evidence on their effectiveness, topical antibiotics and antiseptics are commonly employed. Due to the colonization of bacteria and the presence of biofilms in the sinus tracts formed by HS lesions, systemic antibiotics are commonly employed as the primary form of therapy. In females with HS who experience menstrual flares or display symptoms of polycystic ovary syndrome, hormonal agents are often considered to be a viable and effective therapeutic option. At present, the sole treatment approved by both the Food and Drug Administration and the European Medicines Agency for addressing moderate to severe HS is adalimumab, an antibody that targets tumor necrosis factor alpha. Many surgical procedures in the management of HS aim to address inflammation by eliminating the affected folliculo-pilosebaceous unit, sinus tracts, and associated debris to impede further progression and scarring. HS continues to pose a considerable treatment challenge, necessitating a comprehensive approach for patients. However, the available evidence for most of these treatments is limited, indicating the need for more extensive research to identify the most effective interventions for managing HS.

Insights into New-onset Arthritis in Patients with Hidradenitis Suppurativa

An Update on Hidradenitis Suppurativa (Part I): Epidemiology, Clinical Aspects, and Definition of Disease Severity

Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study

Hidradenitis Suppurativa from a Multi-Omic Scope

The Nationwide Epidemiology of Patients Treated for Hidradenitis Suppurativa by a Dermatologist in the Faroe Islands

Prevalence and Predictors of Inflammatory Arthritis in Hidradenitis Suppurativa

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

Profound Sexual Dysfunction Among Patients with Hidradenitis Suppurativa: A Cross-sectional Study

The most recent advances in understanding and managing hidradenitis suppurativa

Prevalence of Musculoskeletal Symptoms in Patients With Hidradenitis Suppurativa and Associated Factors: Cross-Sectional Study

Real‐world adalimumab survival and discontinuation factors in hidradenitis suppurativa

Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study

Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study

Epidemiology of Hidradenitis Suppurativa: Current Status

Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution

P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management—A Systematic Review

Insights into Gut Microbiome Composition in Hidradenitis Suppurativa: A Comprehensive Examination of Dietary Habits and Environmental Influences

S1131 Disease Outcomes in Patients With Inflammatory Bowel Disease and Concurrent Hidradenitis Suppurativa: A Nationwide Cohort Study

Clinical Epidemiology and Management of Hidradenitis Suppurativa

Hidradenitis Suppurativa: A Literature Review Comparing Current Therapeutic Modalities